Djibouti vs Yemen: Share of the population living with HIV receiving antiretroviral therapy
Djibouti
24.7%
in 2024
Yemen
28.7%
in 2024
Djibouti rank
145th
Yemen rank
144th
Share of the population living with HIV receiving antiretroviral therapy over time
- Djibouti
- Yemen
How they compare
Yemen currently reports 28.7% against 24.7% in Djibouti, a difference of 4.0%.
That makes Yemen's figure about 1.2 times Djibouti's.
The two have swapped places 4 times across 34 shared years of data; in 1990 it was Yemen ahead.
Djibouti ranks 145th and Yemen ranks 144th of 149 countries.
Across the 4 decades both report, Djibouti averaged higher in 1 and Yemen in 2.
Head to head by decade
| Decade | Djibouti | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 2.2% | 1.0% | 1.2% | Djibouti |
| 2010s | 14.4% | 14.5% | 0.2% | Yemen |
| 2020s | 22.6% | 25.7% | 3.1% | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Djibouti or Yemen?
- Yemen, at 28.7% against 24.7% in Djibouti as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Djibouti and Yemen?
- 4.0%, with Yemen ahead.
- How many years of comparable data are there for Djibouti and Yemen?
- 34 years are reported by both, from 1990 to 2024.
- How do Djibouti and Yemen rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Djibouti ranks 145th and Yemen ranks 144th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.